Annovis Bio, Inc.: Business Overview, Financials & Competitive Analysis
Annovis Bio, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Strong Buy consensus from analysts as of January 2026, supported by near-term clinical catalysts and potential disease-modifying efficacy in major indications. Analysts rate the company as Strong Buy with a consensus rating from 2 analysts, though the company faces significant financing risks and pipeline challenges in neurodegenerative disease development.
What is Annovis Bio, Inc.'s industry? Annovis Bio, Inc. (annovisbio.com) operates in Biotechnology / Neuroscience. AskCyborg classifies Annovis Bio, Inc. under Biotechnology / Neuroscience in its company registry.
Annovis Bio is a clinical-stage drug platform company developing drugs to treat neurodegeneration, with its lead product candidate Buntanetap in phase 2/3 for Alzheimer's disease and phase 3 for Parkinson's disease. T...
Cyborg Score thesis
Strong Buy consensus from analysts as of January 2026, supported by near-term clinical catalysts and potential disease-modifying...
Read the full analyst-debate transcript →Get the Latest Annovis Bio, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAnnovis Bio, Inc. Overview
Pro stress-test →Annovis Bio is a clinical-stage drug platform company developing drugs to treat neurodegeneration, with its lead product candidate Buntanetap in phase 2/3 for Alzheimer's disease and phase 3 for Parkinson's disease. The company targets a critical unmet need in neurodegenerative disease treatment with significant clinical and commercial opportunity.
Strategic Profile
Pro stress-test →The company is on schedule for its first 6-month readout in 2026 from its pivotal Phase 3 study enrolling 760 Alzheimer's patients, with dual evaluation of symptomatic efficacy at 6 months and disease-modifying response at 18 months. Annovis is also launching an Open-Label Extension study for Parkinson's disease in January 2026 targeting 500 patients, positioning the company for potential regulatory pathway advancement.
Competitive Landscape
Pro stress-test →Annovis targets challenging neurodegenerative conditions and faces competition in Alzheimer's and Parkinson's disease markets with risks related to trial failures and FDA approval concerns. The competitive environment includes established players and emerging biotech companies developing disease-modifying and symptomatic treatments for these large markets.
Industry Context
Annovis Bio, Inc. operates in Biotechnology / Neuroscience.
Key facts
Founded: 2008 · Headquarters: Malvern, Pennsylvania · Employees: 8 · Market cap: $93M